Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

NCT00446225 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

174

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Carboplatin
DRUG: Gemcitabin
DRUG: Docetaxel
DRUG: Cisplatin

Sponsor

Spanish Lung Cancer Group